FDA Grants AP Status for Clindamycin Phosphate Supplement by ALMAJECT
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement of Clindamycin Phosphate submitted by ALMAJECT.
Asset / Drug
Drug and asset intelligence for ALMAJECT with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.